古田 恵 (フルタ メグミ)

北海道大学病院 男女共同参画推進室特任助教

研究者基本情報

■ 学位
  • 博士(医学), 北海道大学, 2019年
■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 呼吸器内科学

経歴

■ 経歴
学歴
  • 2015年04月 - 2019年03月, 北海道大学大学院, 大学院医学研究科
  • 2003年04月 - 2009年03月, 旭川医科大学, 医学部, 医学科

研究活動情報

■ 受賞
  • 2013年, 第53回日本呼吸器学会学術講演会, 研修医トラベルアワード
    当院で経験した肺動静脈ろうの臨床的特徴
    古田恵
■ 論文
  • Clinical characteristics of long-term survivors of small cell lung cancer.
    Yuki Hatakeyama; Daisuke Morinaga; Jun Sakakibara-Konishi; Riku Azuma; Kosuke Tsuji; Shotaro Ito; Tomohiko Nakamura; Yuta Takashima; Tetsuaki Shoji; Megumi Furuta; Tomohiro Goda; Hidenori Kitai; Yasuyuki Ikezawa; Satoshi Konno
    Respiratory investigation, 64, 4, 101468, 101468, 2026年07月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Small cell lung cancer (SCLC) is an aggressive disease with poor prognosis. Long-term survivors (LTS) are rare, and factors associated with LTS remain unclear. This study investigated the characteristics and treatment outcomes of LTS with SCLC. METHODS: Patients diagnosed with SCLC who received systemic therapy between 2007 and 2025 were retrospectively reviewed. LTS were defined as those surviving ≥18 months. Baseline clinical features, laboratory data, and treatment outcomes were compared between LTS and non-LTS. RESULTS: Among 217 patients, 60 were LTS. LTS were younger and had better performance status, recurrence after surgery or chemoradiotherapy, fewer liver and bone metastases, fewer metastatic organs, lower tumor burden, and lower neutrophil-to-lymphocyte ratios (NLR). In the multivariate analysis, younger age, lower tumor burden, and lower NLR were independently associated with LTS. The proportion of LTS did not differ between patients treated with or without immune checkpoint inhibitors (ICIs). LTS showed significantly longer progression-free survival (PFS) after first-line therapy and also maintained longer PFS across second- to fourth-line treatments, indicating sustained chemosensitivity. ICI-containing regimens tended to improve PFS and overall survival in both groups, though the degree of benefit varied. CONCLUSIONS: LTS with SCLC were characterized by favorable baseline features, particularly younger age, lower tumor burden, and lower NLR, as well as sustained responsiveness to later-line chemotherapy.
  • Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.
    Ryosuke Tsugitomi; Kento Takagi; Go Saito; Motoko Tachihara; Hironori Ashinuma; Takehito Shukuya; Shinnosuke Takemoto; Shinya Sakata; Atsuto Mouri; Hideki Miwa; Yosuke Tamura; Takaaki Tokito; Yoko Tsukita; Yoshihito Kogure; Takeshi Masuda; Hiroshi Tanaka; Sousuke Kubo; Takaaki Sasaki; Tomohiro Oba; Nobuaki Mamesaya; Taro Yamanaka; Hiromi Nagashima; Motohiro Tamiya; Hiroaki Kanemura; Takehiro Tozuka; Megumi Furuta; Hayato Kawachi; Takashi Ninomiya; Yoshiaki Nagai; Hirokazu Ogino; Kentaro Ito; Masashi Ishihara; Takuji Suzuki
    Lung cancer (Amsterdam, Netherlands), 214, 109309, 109309, 2026年04月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Thymic carcinoma is a rare thoracic malignancy with limited first-line treatment options. Lenvatinib has shown efficacy and tolerability in previously treated patients, but its role in chemotherapy-naive patients is unclear. METHODS: We conducted a retrospective, multicentre observational study across 31 Japanese institutions. Patients with advanced or recurrent thymic carcinoma who received lenvatinib between 23 March 2021 and 31 October 2022 were included. Data cut-off was 13 November 2024. Outcomes for chemotherapy-naive patients included objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and adverse events (AEs). Subgroup analyses were stratified by age. RESULTS: Of 107 patients, 20 received lenvatinib as first-line therapy. Median observation was 23.6 months (interquartile range, 12.5-27.1). ORR was 50% (90% confidence interval [CI], 27.2-72.8%), and DCR 85% (95% CI, 62.1-96.8%). Median PFS, TTF, and OS were 10.9 months (95% CI, 5.6-17.1), 8.9 months (95% CI, 5.3-17.8), and 25.0 months (95% CI, 21.2-not reached). AEs occurred in 95% (Grade ≥ 3 in 60%); dose reductions and discontinuations occurred in 85% and 25%. Safety was consistent with prior reports. Older patients showed higher rates of Grade ≥ 3 AEs and discontinuation. CONCLUSIONS: In this real-world cohort, first-line lenvatinib demonstrated favourable efficacy and manageable safety, supporting its use in advanced or recurrent thymic carcinoma.
  • Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non-Small Cell Lung Cancer: A Case Report.
    Daisuke Morinaga; Megumi Furuta; Doppo Fukui; Yuki Matsuura; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Hidenori Kitai; Zenichi Tanei; Jun Sakakibara-Konishi; Satoshi Konno
    Clinical lung cancer, 27, 2, 117, 120, 2026年03月, [国際誌]
    英語, 研究論文(学術雑誌)
  • Limited-Stage Small-Cell Lung Cancer With Severe Paraneoplastic Limbic Encephalitis Successfully Treated With Chemoradiotherapy Followed by Immune Checkpoint Inhibitor Maintenance Therapy: A Case Report.
    Daisuke Morinaga; Hidenori Kitai; Hanko Sato; Doppo Fukui; Wataru Harabayashi; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Megumi Furuta; Akihiko Kudo; Shintaro Fujii; Hisashi Uwatoko; Hiroaki Yaguchi; Keiko Tanaka; Ichiro Yabe; Jun Sakakibara-Konishi; Satoshi Konno
    Clinical lung cancer, 27, 2, 121, 125, 2026年03月, [国際誌]
    英語, 研究論文(学術雑誌)
  • A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy.
    Doppo Fukui; Daisuke Morinaga; Jun Sakakibara-Konishi; Yukiko Yoshida; Masahiro Kashima; Shotaro Ito; Megumi Furuta; Yuta Takashima; Zenichi Tanei; Satoshi Konno
    Respiratory investigation, 64, 2, 101375, 101375, 2026年01月20日, [国際誌]
    英語, 研究論文(学術雑誌), A comprehensive pathological evaluation is useful for diagnosing synchronous multiple primary lung cancer (sMPLC). However, a consensus regarding treatment for sMPLC with different driver mutations is lacking. We present a case of sMPLC harboring an epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) fusion gene. For the advanced EGFR-positive tumor, osimertinib plus chemotherapy was initiated, the latter also covering ALK-positive tumor. A marked response and slight reduction occurred in the EGFR-positive and ALK-positive tumors, respectively. Surgical resection of the ALK-positive tumor achieved negative margins. Targeted therapy with chemotherapy may effectively treat sMPLC with different driver mutations.
  • Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case report.
    Chisa Murayama; Yasuyuki Ikezawa; Chihiro Shiiya; Yoshitaka Oda; Masafumi Ikezawa; Akihiro Matsunaga; Kosuke Tsuji; Tetsuaki Shoji; Megumi Furuta; Yuta Takashima; Hidenori Kitai; Jun Sakakibara-Konishi; Satoshi Konno
    Respiratory medicine case reports, 61, 102421, 102421, 2026年, [国際誌]
    英語, 研究論文(学術雑誌), Immune checkpoint inhibitors, such as atezolizumab, have become integral to the treatment of various malignancies and have significantly improved clinical outcomes by enhancing host antitumor immune responses. However, with their expanding clinical use, immune-related adverse events (irAEs) have been increasingly recognized. These events may involve any organ system and pose new challenges in patient management. Most irAEs occur within the first few months following treatment initiation; however, they may also develop unexpectedly after prolonged periods of stable therapy. Late-onset irAEs are generally mild to moderate in severity, although a subset can progress to severe forms. Dermatological toxicities are the most frequently observed irAEs. Although most cutaneous reactions are mild and manageable, severe skin toxicities, although relatively uncommon, can substantially impair patients' quality of life and may necessitate treatment modification or discontinuation. Psoriasis is a recognized cutaneous irAE that may present either as a de novo disease in patients without a history of psoriasis or as an exacerbation of pre-existing psoriasis. This case report describes a rare presentation of severe psoriasis that developed following long-term atezolizumab therapy and improved following treatment with oral prednisolone in 61-year-old man with pulmonary large-cell neuroendocrine carcinoma.
  • Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
    村山 千咲; 池澤 靖元; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 英典; 榊原 純; 今野 哲; 椎谷 千尋; 小田 義崇
    肺癌, 65, 7, 1093, 1094, (NPO)日本肺癌学会, 2025年12月
    日本語
  • A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).
    Daisuke Morinaga; Megumi Furuta; Satoshi Morita; Eisaku Miyauchi; Kunihiko Kobayashi; Makoto Maemondo; Hajime Asahina
    Clinical lung cancer, 26, 8, 611, 616, 2025年12月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: In treatment-naïve advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, approximately 10% to 15% correspond to uncommon mutations. For patients with EGFR uncommon mutations, monotherapy with either a second-generation EGFR tyrosine kinase inhibitor (TKI), afatinib, or a third-generation EGFR-TKI, osimertinib, is recommended as the initial therapy. However, needs remain unmet for patients with central nervous system (CNS) metastases and those who do not respond adequately to single-agent TKI therapy for EGFR uncommon mutations. The recently published FLAURA2 trial showed that osimertinib in combination with platinum-pemetrexed significantly prolonged progression-free survival (PFS) and provided high disease control compared with osimertinib monotherapy for common mutations. Therefore, we planned this phase II study to evaluate the efficacy and safety of osimertinib in combination with platinum-pemetrexed in treatment-naïve NSCLC patients with EGFR uncommon mutations. PATIENTS AND METHODS: Forty patients will be enrolled in the study. The primary endpoint is the objective response rate, and the secondary endpoints include safety, PFS and overall survival in overall patients, patients with and without CNS lesions at baseline and according to mutation subtype. CONCLUSIONS: In this study, we will explore the efficacy and safety of osimertinib in combination with platinum-pemetrexed in treatment-naïve NSCLC patients with EGFR uncommon mutations. Our findings may provide treatment options for patients with EGFR uncommon mutations, especially those with CNS metastases or those requiring more intensive treatment.
  • EGFR uncommon変異陽性未治療非小細胞肺癌に対するosimertinib+プラチナ併用療法の第II相試験(NEJ067)
    古田 恵; 森永 大亮; 森田 智視; 宮内 栄作; 小林 国彦; 前門戸 任; 朝比奈 肇
    肺癌, 65, 5, 735, 735, (NPO)日本肺癌学会, 2025年11月
    日本語
  • Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
    村山 千咲; 池澤 靖元; 椎谷 千尋; 小田 義崇; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 榊原 純; 今野 哲
    肺癌, 65, 5, 671, 671, (NPO)日本肺癌学会, 2025年11月
    日本語
  • Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer.
    Shotaro Ito; Jun Sakakibara-Konishi; Mineyoshi Sato; Tetsuaki Shoji; Megumi Furuta; Hirofumi Takahashi; Kosuke Tsuji; Daisuke Morinaga; Masahiro Kashima; Hidenori Kitai; Junko Kikuchi; Eiki Kikuchi; Kanako C Hatanaka; Yutaka Hatanaka; Kyoko Hida; Takuro Noguchi; Satoshi Konno
    Cancer medicine, 14, 13, e71034, 2025年07月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive disease associated with poor patient survival rates. The addition of an anti-programmed death ligand 1 antibody to platinum combination chemotherapy can improve its prognosis. However, only a few patients achieve a long-term response; thus, establishing new therapies for SCLC is crucial. Midkine (MDK) is a heparin-binding growth factor involved in various biological processes, including cell proliferation and chemotherapeutic resistance, in diverse cancers. MDK has garnered attention as a therapeutic and diagnostic target for several cancers; however, only a few studies have evaluated its expression and function in SCLC. This study aimed to evaluate the MDK expression in human SCLC tissue and human SCLC cell lines, and to clarify its function in tumorigenesis. METHODS: MDK expression was analyzed in vitro and in vivo through ELISA, immunohistochemistry, and western blotting. Its effects on cell proliferation, as well as the effects of cisplatin, were evaluated using the MTT assay. RESULTS: MDK was pathologically expressed in human SCLC tumor tissues but not in normal lung tissues. Serum MDK concentrations in patients with SCLC reflected the SCLC tumor burden and were correlated with response to treatment. Moreover, MDK induced cell proliferation and attenuated the effects of cisplatin in SCLC cell lines. An MDK inhibitor and cisplatin exerted synergistic antitumor effects both in vitro and in vivo. Furthermore, MDK positively regulated the AKT pathway. CONCLUSION: Our findings indicate that MDK promotes cell proliferation and chemotherapeutic resistance by activating the AKT pathway in SCLC cells. Therefore, MDK may be a potential therapeutic and diagnostic target for SCLC.
  • Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
    Daisuke Morinaga; Jun Sakakibara-Konishi; Ryohei Kamada; Masahiro Kashima; Kosuke Tsuji; Shotaro Ito; Megumi Furuta; Tetsuaki Shoji; Yuta Takashima; Hidenori Kitai; Yasuyuki Ikezawa; Hiroshi Taguchi; Tatsuya Kato; Yoshiki Shinomiya; Kanako C Hatanaka; Yutaka Hatanaka; Satoshi Konno
    Thoracic cancer, 16, 13, e70119, 2025年07月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP. METHODS: A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy. RESULTS: Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights. CONCLUSIONS: Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
  • 低用量のセルペルカチニブが奏効したRET融合遺伝子陽性非小細胞肺癌の1例
    島田 琉海; 庄司 哲明; 高橋 宏典; 猪狩 智生; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲; 伊藤 健一郎; 福土 将秀
    肺癌, 65, 3, 205, 205, (NPO)日本肺癌学会, 2025年06月
    日本語
  • 術前化学免疫療法1コースで免疫関連有害事象により外科切除に移行し病理学的奏効を得た肺扁平上皮癌の1例
    鎌田 凌平; 庄司 哲明; 池澤 靖元; 久世 瑞穂; 東 陸; 松永 章宏; 畠山 酉季; 辻 康介; 高橋 宏典; 高島 雄太; 古田 恵; 北井 秀典; 榊原 純; 今野 哲; 宮石 陸; 大塚 紀幸; 田中 伸哉; 加藤 達哉
    肺癌, 65, 3, 207, 207, (NPO)日本肺癌学会, 2025年06月
    日本語
  • Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancer.
    Daisuke Morinaga; Kana Hashimoto; Hajime Asahina; Hisashi Tanaka; Osamu Honjo; Toshiyuki Harada; Hiroshi Yokouchi; Hajime Kikuchi; Ryota Shigaki; Taichi Takashina; Keiichi Nakamura; Yasutaka Kawai; Mamoru Takahashi; Ryotaro Kida; Noriaki Sukoh; Kenichiro Ito; Ayumu Takahashi; Fumihiro Hommura; Yoshihito Ohhara; Megumi Furuta; Satoshi Konno; Yukio Hosomi; Satoshi Oizumi
    Respiratory investigation, 63, 3, 373, 382, 2025年05月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Immune checkpoint inhibitor plus chemotherapy (ICT) is the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). We previously reported that oligometastasis (OM) is a predictor of ICT efficacy, however, the relationship between ICT efficacy and OM in older patients remains unknown. Therefore, this study examined the efficacy of ICT in the older patients including the influence of OM. METHODS: We enrolled patients with ES-SCLC who received ICT as first-line treatment between September 2019 and June 2022. Patient characteristics and treatment efficacy were compared between older (≥75 years) and non-older (<75 years) patients. RESULTS: We enrolled 228 patients, including 42 older patients. The prevalence of synchronous oligometastasis (SOM) at the start of first-line treatment was 21.0 % and 21.4 % (p = 1.0) in the older and non-older groups, respectively. The progression-free survival (PFS) with first-line therapy was 5.4 and 4.5 months (p = 0.55) and overall survival (OS) was 11.5 and 12.6 months (p = 0.74) for the SOM and non-SOM subgroups in the older group, respectively. For second-line treatment, PFS was 4.5 and 6.3 months (p = 0.79), and OS after second-line initiation was 16.0 and 13.2 months (p = 0.55) in oligoprogression (OP) and non-OP patients in the older group, respectively. CONCLUSIONS: The frequencies of SOM and OP were not significantly different between older and non-older patients. Although the small number of older patients in this study makes it impossible to conclude definitively, we did not observe a significant prognostic prolongation in older patients with OM as in non-older patients.
  • Evaluating the Usefulness of the Insertion Tube Rotation Function of Bronchoscope in Cadaver Models.
    Naofumi Shinagawa; Yuta Takashima; Masahiro Kashima; Daisuke Morinaga; Shotaro Ito; Kosuke Tsuji; Mineyoshi Sato; Hirofumi Takahashi; Tetsuaki Shoji; Megumi Furuta; Toshiaki Shichinohe; Satoshi Konno
    Journal of bronchology & interventional pulmonology, 32, 2, 2025年04月01日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The Olympus bronchoscope is equipped with an insertion tube rotation function; however, data on its usefulness are currently limited. Here, we evaluated the amount of body and wrist movement required by bronchoscopists, the operability of the bronchoscope, and its ease of use with and without the insertion tube rotation function. METHODS: This study was performed on 10 bronchoscopists using 2 cadaveric bodies. The primary endpoint was the amount of movement exerted by the bronchoscopist, which was evaluated using motion capture. We also assessed the deepest bronchial generations that could be reached by the bronchoscope and the time required for insertion. Immediately after the procedures, the bronchoscopists completed a questionnaire to evaluate their perceived difficulty level. RESULTS: The bronchoscopists achieved a 33.5% reduction in wrist rotation (67.8 vs. 110.2 degrees, P<0.05) and a 23.9% reduction in body rotation (17.2 vs. 24.4 degrees, P<0.05) using the insertion tube rotation function for all segmental bronchi. During forceps insertion to simulated lesions, the bronchoscopists' body movement was reduced by 65.1% (11.6 vs. 33.9 degrees, P<0.05), and wrist rotation by 47.6% (63.5 vs. 122.7 degrees, P<0.05). Furthermore, bronchoscopists experienced significantly reduced difficulty inserting biopsy forceps toward simulated target lesions (3.9 vs. 3.2 points, P<0.05) and required less assistance (4.0 vs. 2.0 points, P<0.05) when using the insertion tube rotation function. CONCLUSION: The insertion tube rotation function of the bronchoscope facilitated its insertion and improved operability.
  • Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
    Kazunari Tateishi; Hidenori Mizugaki; Yasuyuki Ikezawa; Ryo Morita; Keiki Yokoo; Toshiyuki Sumi; Mari Aso; Hajime Kikuchi; Atsushi Nakamura; Motoki Sekikawa; Fumiaki Yoshiike; Yasuo Kitamura; Nozomu Kimura; Tsutomu Hachiya; Kyoji Tsurumi; Toshihiko Agatsuma; Furuta Megumi; Keiichi Nakamura; Daisuke Jingu; Hiroshi Yamamoto; Makoto Kosaka; Hiroshi Yokouchi
    Japanese journal of clinical oncology, 55, 3, 253, 260, 2025年03月05日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed to determine whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected. METHODS: We performed a retrospective multicenter study (sub-analysis of the HOT/NJLCG2001 trial) of 299 patients with NSCLC with high PD-L1 expression who received MONO or COMB as the first-line treatment between December 2018 and January 2020. We selected patients aged 75 years and older and assessed the clinical efficacy and toxicity. RESULTS: In total, 81 (median age: 79 years) and 19 (median age: 76 years) patients received MONO and COMB, respectively. Twenty patients with a performance status (PS) score of 2-3 were enrolled in the MONO group. The median progression-free survival (PFS) was 7.8 and 8.9 months in the MONO and COMB groups, respectively. The median overall survival (OS) was 14.6 and 20.3 months, and the 2-year survival rates were 38.8 and 49.9%, respectively. Furthermore, 29.6% and 26.3% of patients discontinued treatment due to adverse events, respectively. In MONO, patients with PS 0-1 had a longer PFS (10.5 months) and OS (21.7 months) than those with PS 2-3 (0.7 and 1.6 months, respectively). CONCLUSION: Some elderly patients with NSCLC and high PD-L1 expression might benefit from COMB; however, MONO is considered the preferred treatment. MONO may not be an effective or feasible treatment for patients with PS 2-3, even with high PD-L1 expression.
  • 経過中に腹膜播種による腹水が乳び化を呈した,胸腺腫の1例
    武藤 ほの; 庄司 哲明; 古川 貴啓; 辻 康介; 佐藤 峰嘉; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 木野田 直也; 阿保 大介; 榊原 純; 今野 哲
    日本呼吸器学会誌, 14, 増刊, 366, 366, (一社)日本呼吸器学会, 2025年03月
    日本語
  • 医学部生におけるダイバーシティ(男女共同参画、キャリアに関する意識調査)
    古田 恵; 清水 薫子; 菅野 恭子; 今野 哲; 高橋 誠; 山本 明美; 渥美 達也
    北海道医報, 1277, 14, 16, 北海道医師会, 2025年02月
    日本語
  • 気管支狭窄拡張術後にALK-TKIを導入したHIP1-ALK陽性肺癌の1例
    佐藤 祐麻; 北井 秀典; 田上 敬太; 石田 有莉子; 篠崎 鮎香; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 庄司 哲明; 池澤 靖元; 榊原 純; 品川 尚文; 今野 哲; 大川 紘弥; 大塚 紀幸; 畑中 佳奈子; 畑中 豊; 横内 浩
    肺癌, 65, 1, 65, 65, (NPO)日本肺癌学会, 2025年02月
    日本語
  • 全身療法中にoligoprogression/oligorecurrenceを認めた非小細胞肺癌症例の検討
    鎌田 凌平; 森永 大亮; 榊原 純; 古川 貴啓; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 庄司 哲明; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 田口 大志; 加藤 達哉
    肺癌, 65, 1, 66, 67, (NPO)日本肺癌学会, 2025年02月
    日本語
  • 小細胞肺癌との鑑別に苦慮した胸部SMARCA4欠損未分化腫瘍の1例
    溝渕 匠平; 榊原 純; 棟方 奈菜; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 加藤 憲士郎; 大塚 紀幸; 種井 善一; 田中 伸哉
    肺癌, 65, 1, 67, 67, (NPO)日本肺癌学会, 2025年02月
    日本語
  • EGFR遺伝子変異陽性進行再発非小細胞肺癌における免疫チェックポイント阻害剤の治療についての後方視的検討
    古川 貴啓; 庄司 哲明; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲
    肺癌, 65, 1, 68, 68, (NPO)日本肺癌学会, 2025年02月
    日本語
  • Rapid disease progression and hydrocephalus following tarlatamab therapy initiation: A case report.
    Doppo Fukui; Jun Sakakibara-Konishi; Riku Azuma; Yukiko Yoshida; Daisuke Morinaga; Shotaro Ito; Megumi Furuta; Yuta Takasihma; Hidenori Kitai; Satoshi Konno
    Respiratory medicine case reports, 58, 102324, 102324, 2025年, [国際誌]
    英語, 研究論文(学術雑誌), Tarlatamab is a novel bispecific T-cell engager immunotherapy that has demonstrated efficacy against small-cell lung cancer (SCLC) in terms of noteworthy anticancer activity and survival outcomes. However, no studies have detailed the patterns of disease progression during tarlatamab treatment. Herein, we present a case of acute disease progression after tarlatamab initiation in a 71-year-old male patient with extensive-stage SCLC. Following tarlatamab administration, he developed symptoms of cognitive impairment, which raised suspicion of immune effector cell-associated neurotoxicity syndrome (ICANS), an adverse event associated with the drug. Diagnostic evaluation revealed that the symptoms were caused by obstructive hydrocephalus due to worsening brain metastases. Following tarlatamab administration, we observed rapid progression of the previously indolent SCLC, leading to deterioration in the patient's overall condition. This case highlights the need to consider the possibility of rapid disease progression following tarlatamab administration and underscores the importance of adequate assessment to exclude ICANS. Since rapid tumor progression may lead to a decline in the patient's general condition, careful follow-up is advised.
  • Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report.
    Yuki Hatakeyama; Jun Sakakibara-Konishi; Masato Tarumi; Kosuke Tsuji; Hirofumi Takahashi; Megumi Furuta; Yuta Takashima; Hidenori Kitai; Tetsuaki Shoji; Yasuyuki Ikezawa; Satoshi Konno
    Respiratory medicine case reports, 54, 102181, 102181, 2025年, [国際誌]
    英語, 研究論文(学術雑誌), Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that study; therefore, the efficacy and safety of lenvatinib in these patients remain unknown. Herein, we report the case of a woman in her 50s who was diagnosed with thymic carcinoma complicated with ILD. In August 2016, the patient developed ILD with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM). She received triple therapy comprising prednisolone, tacrolimus and azathioprine. In October 2021, the patient complained of lateral chest pain and back pain. In January 2022, computed tomography (CT) revealed an anterior mediastinal tumor, and percutaneous biopsy resulted in a diagnosis of thymic carcinoma with Masaoka classification IVb. In March 2022, first-line treatment with four cycles of carboplatin (area under the curve, 6) + paclitaxel (200 mg/m2) was initiated. Although a partial response was achieved, in September 2022, CT demonstrated progressive disease (PD). Therefore, in October 2022, Lenvatinib (24 mg) was started as the second-line treatment. The best response was stable disease; moreover, although lenvatinib dose reduction was required owing to adverse events, such as biliary-tract infection and stomatitis. The patient did not experience ILD exacerbation. Lenvatinib (14 mg) was continued until PD was observed in March 2023. Our findings suggest that lenvatinib is a viable treatment option for thymic carcinoma with ILD.
  • Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
    Jun Sakakibara-Konishi; Hirofumi Takahashi; Kenichiro Ito; Tomoo Ikari; Yasuyuki Ikezawa; Hidenori Kitai; Megumi Furuta; Yuta Takashima; Tetsuaki Shoji; Masahide Fukudo; Satoshi Konno
    Respiratory Medicine Case Reports, 53, 102176, 102176, Elsevier BV, 2025年, [国際誌]
    英語, 研究論文(学術雑誌), Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1-2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly tolerable adverse events. However, hypertension, aspartate aminotransferase increase, and alanine aminotransferase increase are the most common adverse events, and dose modification or discontinuation is required occasionally. Here, we describe a case who has response to 40 mg of selpercatinib every other day because the dose had to be adjusted owing to adverse events such as liver dysfunction. Dose modification of selpercatinib, according to adverse event incidences, may be considered, as selpercatinib may be effective in some cases even at very low concentrations.
  • Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301).
    Kana Hashimoto; Daisuke Morinaga; Hajime Asahina; Mina Ishidoya; Hajime Kikuchi; Hiroshi Yokouchi; Toshiyuki Harada; Osamu Honjo; Ryota Shigaki; Taichi Takashina; Yuka Fujita; Mamoru Takahashi; Yasutaka Kawai; Ryotaro Kida; Kenichiro Ito; Noriaki Sukoh; Ayumu Takahashi; Fumihiro Hommura; Yoshihito Ohhara; Megumi Furuta; Satoshi Konno; Yukio Hosomi; Satoshi Oizumi
    JTO clinical and research reports, 5, 11, 100715, 100715, 2024年11月, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic impact of oligometastasis and OP in ES-SCLC. METHODS: We enrolled patients who received chemoimmunotherapy between September 2019 and June 2022. Patients were classified into oligometastasis and non-oligometastasis groups by determining the number of original tumor lesions and distant metastases (worsening or newly appearing lesions) at the time of initial diagnosis and disease progression after first-line treatment. RESULTS: We retrospectively analyzed 265 consecutive patients with ES-SCLC. Synchronous oligometastasis (SOM) and OP was defined as less than or equal to five lesions in less than or equal to two organs, including lungs; 21.0% and 53.2% of patients had SOM and OP, respectively. Median progression-free survival was 5.8 months and 4.9 months in patients with and without SOM, respectively (hazard ratio [HR] = 0.72, 95% confidence interval [CI]: 0.51-1.02, p = 0.065). Median overall survival was 20.5 months and 15.0 months in patients with and without SOM (HR = 0.58, 95% CI: 0.37-0.95, p = 0.027) from the initiation of first-line treatment. The OP group revealed a better progression-free survival of 5.2 months (versus 3.2 mo, HR = 0.69, 95% CI: 0.50-0.96, p = 0.026) and overall survival of 15.1 months (versus 7.5 mo, HR = 0.44, 95% CI: 0.29-0.66, p = 0.027) from the initiation of second-line treatment compared with the non-OP group. The Lung Immune Prognostic Index score was significantly lower in the SOM and OP group. CONCLUSIONS: ES-SCLC in patients with SOM and OP may be more indolent than that of the nonoligometastasis group, therefore, new treatment strategies, including the addition of local treatment, should be explored. CLINICAL TRIAL REGISTRATION: This study was registered at UMIN-CTR (UMIN000053402).
  • Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
    Megumi Furuta; Hidehito Horinouchi; Isao Yokota; Teppei Yamaguchi; Shoichi Itoh; Takafumi Fukui; Akira Iwashima; Jun Sugisaka; Yu Miura; Hisashi Tanaka; Taichi Miyawaki; Hiroshi Yokouchi; Keita Miura; Ryota Saito; Go Saito; Tatsuhiko Kamoshida; Yusuke Uchinami; Tatsuya Kato; Kunihiko Kobayashi; Hajime Asahina
    Cancer science, 115, 11, 3705, 3717, 2024年11月, [国際誌]
    英語, 研究論文(学術雑誌), Locoregional recurrence of non-small-cell lung cancer (NSCLC) after complete resection lacks standard treatment. Durvalumab after chemoradiotherapy (CRT) or CRT alone is often selected in daily clinical practice for patients with locoregional recurrence; however, the therapeutic efficacy of these treatments remains unclear, and we aimed to assess this. This retrospective observational study used data from patients with NSCLC diagnosed with locoregional recurrence after complete resection who subsequently underwent concurrent CRT followed by durvalumab (CRT-D group) or CRT alone (CRT group). We employed propensity score analysis with inverse probability treatment weighting (IPTW) to adjust for various confounders and evaluate efficacy in the CRT-D group. After IPTW adjustment, the CRT-D group contained 119 patients (64.7% male; 69.7% adenocarcinoma), and the CRT group contained 111 patients (60.5% male; 73.4% adenocarcinoma). Their mean ages were 66 and 65 years, respectively. The IPTW-adjusted median progression-free survival was 25.4 and 11.5 months for the CRT-D and CRT groups, respectively (hazard ratio, 0.44; 95% confidence interval, 0.30-0.64); the median overall survival was not reached in either group favoring CRT-D (hazard ratio, 0.49; 95% confidence interval, 0.24-0.99). Grade 3 or 4 adverse events were observed in 48.8% of patients during CRT, 10.7% after initiating durvalumab maintenance therapy in the CRT-D group, and 57.3% in the CRT group. Overall, the sequential approach of CRT followed by durvalumab is a promising treatment strategy for locoregional recurrence of NSCLC after complete resection.
  • Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
    Yasuyuki Ikezawa; Ryo Morita; Hidenori Mizugaki; Kazunari Tateishi; Keiki Yokoo; Toshiyuki Sumi; Hajime Kikuchi; Yasuo Kitamura; Atsushi Nakamura; Maki Kobayashi; Mari Aso; Nozomu Kimura; Fumiaki Yoshiike; Furuta Megumi; Hisashi Tanaka; Motoki Sekikawa; Tsutomu Hachiya; Keiichi Nakamura; Fumihiro Hommura; Noriaki Sukoh; Kenichiro Ito; Takashi Kikuchi; Toshihiko Agatsuma; Hiroshi Yokouchi
    Cancer medicine, 13, 14, e70036, 2024年07月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression is an important issue in clinical practice. We previously conducted a retrospective multicenter observational study of patients with NSCLC and high PD-L1 expression who received MONO or COMB as a first-line treatment. Here, we report updated data and evaluate the long-term outcomes. METHODS: We performed a retrospective multicenter study of 298 patients with NSCLC and high PD-L1 expression who received MONO or COMB as first-line treatment between December 2018 and January 2020. We reviewed the medical records and assessed the clinical efficacy and toxicity using a prolonged data cutoff. RESULTS: In total, 164 (median age: 74 years) and 134 (median age: 68 years) patients received MONO and COMB, respectively; patients who received COMB were younger and had better performance statuses (0-1). At the prolonged data cutoff, the median follow-up was 20.2 (range: 0.1-41.4) months. The median progression-free survivals were 7.5 and 13.1 months, and overall survivals (OSs) were 17.2 and 33.7 months for MONO and COMB, respectively. Treatment discontinuation rates were 21.9% and 20.1% for the MONO and COMB, respectively. With prolonged follow-up, although COMB demonstrated an OS benefit and higher objective response rate than MONO, in the propensity score matching analysis COMB didn't demonstrate a significant benefit compared to the MONO. CONCLUSIONS: COMB may be effective as a first-line treatment for NSCLC with high PD-L1 expression in a selected subset of patients.
  • Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older
    Shigehiro Yagishita; Yuta Yamanaka; Takayasu Kurata; Kageaki Watanabe; Yukio Hosomi; Hidehito Horinouchi; Yuichiro Ohe; Yoshiro Nakahara; Katsuhiko Naoki; Tetsuhiko Asao; Kazuhisa Takahashi; Sho Saeki; Takuro Sakagami; Kazuhisa Nakashima; Yukari Tsubata; Yu Fujita; Hiroshi Wakui; Megumi Furuta; Jun Sakakibara Konishi; Mayu Ohuchi; Yuichi Ando; Hidenori Mizugaki; Akinobu Hamada
    Clinical Pharmacology & Therapeutics, 116, 4, 1042, 1051, Wiley, 2024年06月17日, [国際誌]
    英語, 研究論文(学術雑誌), Pembrolizumab is a major treatment for recurrent or advanced non‐small‐cell lung cancer (NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited. This open‐label, multicenter, observational study evaluated real‐world data on the safety, efficacy, and PK of pembrolizumab in older patients with NSCLC. In 99 patients aged ≥75 years, PK was determined by liquid chromatography–mass spectrometry on pretreatment samples. Performance status (PS), geriatric assessment (GA), overall response rate (ORR), progression‐free survival (PFS), and overall survival (OS) were evaluated. The median age was 78 (75–87) years. PS was 2–3 in 14 patients. The median ORR, PFS, and OS were 47.5%, 8.0, and 20.5 months, respectively. Although PK and ORR were not significantly associated, patients with the lowest Cycle 1‐trough quartile (Q1) experienced poorer PFS (Q1 vs. Q2–4; 3.4 vs. 11.8 months, P = 0.006) and OS (Q1 vs. Q2–4; 9.9 vs. 21.7 months, P = 0.005) than in other quartiles overall, and even in the PD‐L1 ≥50% subset (PFS, Q1 vs. Q2–4; 4.1 vs. 14.7 months, P = 0.005; OS, Q1 vs. Q2–4; 9.4 vs. 22.1 months, P = 0.010). The Q1 subgroup was characterized by poor PS and lower albumin, and more frequent “weight loss ≥ 10%” on the GA. Pembrolizumab therapy had similar PK and efficaciousness in older as well as younger patients. In patients with PS ≥2, low albumin, and vulnerable GA, early increases in PK levels are less likely, potentially diminishing efficacy even when PD‐L1 ≥50%.
  • Epithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report.
    Gaku Yamazaki; Aki Fujiwara-Kuroda; Jun Muto; Hideki Ujiie; Masato Aragaki; Megumi Furuta; Sakurako Ohno; Kanako C Hatanaka; Yutaka Hatanaka; Yoshihiro Matsuno; Tatsuya Kato
    General Thoracic and Cardiovascular Surgery Cases, 3, 1, 31, 31, 2024年06月11日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs) due to their demonstrated efficacy. Here, we present a case of epithelioid-type pleural mesothelioma with chest wall invasion treated with definitive ICI therapy, resulting in a remarkable pretreatment effect. CASE PRESENTATION: A 46-year-old man was diagnosed with an abnormal chest shadow on a medical check, and a computed tomography scan showed pleural thickening at the dorsal right upper chest wall. One of the nodules was suspected to have invaded the chest wall. A needle biopsy revealed epithelioid-type pleural mesothelioma. After five cycles of nivolumab plus ipilimumab, he underwent right pleurectomy/decortication (P/D). Pathological examination revealed a significant treatment effect, showing numerous lymphocytes infiltrating the tumor nodule and viable tumor cells localized at approximately 6 mm. CONCLUSION: Although further accumulation of cases is required to evaluate the effectiveness and case selection, P/D after immunotherapy is a useful curative treatment option for advanced pleural mesothelioma.
  • 80歳以上の高齢者に対する経気管支生検の安全性と有用性の検討
    畠山 酉季; 高島 雄太; 鈴木 孝敏; 棟方 奈菜; 中村 友彦; 高橋 宏典; 古田 恵; 北井 秀典; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
    気管支学, 45, 6, 444, 444, (一社)日本呼吸器内視鏡学会, 2023年11月
    日本語
  • 80歳以上の高齢者に対する経気管支生検の安全性と有用性の検討
    畠山 酉季; 高島 雄太; 鈴木 孝敏; 棟方 奈菜; 中村 友彦; 高橋 宏典; 古田 恵; 北井 秀典; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
    気管支学, 45, Suppl., S217, S217, (一社)日本呼吸器内視鏡学会, 2023年06月
    日本語
  • 術前、術後免疫チェックポイント阻害薬および肺剥皮術による集学的治療を行ったびまん性胸膜中皮腫の1例
    山崎 雅久; 藤原 晶; 千葉 龍平; 野村 俊介; 武藤 潤; 氏家 秀樹; 新垣 雅人; 加賀 基知三; 古田 恵; 大野 桜子; 松野 吉宏; 加藤 達哉
    日本呼吸器外科学会雑誌, 37, 3, O59, 2, (一社)日本呼吸器外科学会, 2023年06月
    日本語
  • Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial.
    Kazutaka Fujita; Ryo Arai; Satoshi Shoji; Ryota Saito; Motoko Nomura; Takamasa Hotta; Hajime Asahina; Masanori Kawakami; Ichiro Nakachi; Yukihiro Hasegawa; Kohei Okafuji; Aya Suzuki; Akihiko Miyanaga; Noriaki Sunaga; Hiromi Nagashima; Naoya Ikeda; Satoshi Watanabe; Yoshiaki Nagai; Megumi Furuta; Hidenori Kage; Daisuke Arai; Tatsuro Fukuhara; Masayuki Nakayama; Satoshi Morita; Kunihiko Kobayashi; Koichi Hagiwara
    Cancer science, 114, 8, 3342, 3351, 2023年05月03日, [国際誌]
    英語, 研究論文(学術雑誌), Most multigene mutation tests require tissue specimens. However, cytological specimens are easily obtained in the clinical practice and provide high-quality DNA and RNA. We aimed to establish a test that utilizes cytological specimens and performed a multi-institutional study to investigate the performance of MINtS, a test based on next-generation sequencing. A standard procedure for specimen isolation was defined. The specimens were considered suitable for the test if >100 ng DNA and >50 ng RNA could be extracted from them. In total, 500 specimens from 19 institutions were investigated. MINtS detected druggable mutations in 63% (136 of 222) of adenocarcinomas. Discordant results between MINtS and the companion diagnostics were observed in 14 of 310 specimens for the EGFR gene, and 6 of 339 specimens for the ALK fusion genes. Confirmation by other companion diagnostics for the EGFR mutations or the clinical response to an ALK inhibitor all supported the results obtained by MINtS. MINtS along with the isolation procedure presented in the current study will be a platform to establish multigene mutation tests that utilize cytological specimens. UMIN000040415.
  • 当科におけるPD-L1陰性非小細胞肺癌に対する免疫チェックポイント阻害薬治療についての後方視的検討
    田上 敬太; 菊地 英毅; 庄司 哲明; 吉川 修平; 黒木 俊宏; 嘉島 相裕; 高木 統一郎; 三浦 瞬; 猪狩 智生; 小熊 昂; 古田 恵; 高島 雄太; 朝比奈 肇; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
    肺癌, 63, 2, 126, 127, (NPO)日本肺癌学会, 2023年04月
    日本語
  • 化学放射線療法+デュルバルマブ療法を施行後に病勢進行となった非小細胞肺癌の次治療の後方視的検討
    嘉島 相裕; 庄司 哲明; 古田 恵; 吉川 修平; 黒木 俊宏; 田上 敬太; 高木 統一郎; 三浦 瞬; 小熊 昂; 猪狩 智生; 高島 雄太; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
    肺癌, 63, 2, 127, 127, (NPO)日本肺癌学会, 2023年04月
    日本語
  • RET融合遺伝子陽性肺腺癌に対してセルペルカチニブ投与後に多彩な有害事象を呈した症例
    関 萌花; 猪狩 智生; 榊原 純; 吉川 修平; 黒木 俊宏; 田上 敬太; 嘉島 相裕; 高木 統一郎; 三浦 瞬; 小熊 昂; 高島 雄太; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲; 伊藤 健一郎
    肺癌, 63, 2, 128, 128, (NPO)日本肺癌学会, 2023年04月
    日本語
  • 非小細胞肺癌での化学放射線+デュルバルマブ療法後の免疫チェックポイント阻害剤再投与の後方視的検討
    嘉島 相裕; 庄司 哲明; 古田 恵; 猪狩 智生; 高島 雄太; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 今野 哲
    日本呼吸器学会誌, 12, 増刊, 278, 278, (一社)日本呼吸器学会, 2023年03月
    日本語
  • Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension.
    Yuta Takashima; Naofumi Shinagawa; Daisuke Morinaga; Junichi Nakamura; Megumi Furuta; Tetsuaki Shoji; Hajime Asahina; Eiki Kikuchi; Junko Kikuchi; Jun Sakakibara-Konishi; Ichizo Tsujino; Satoshi Konno
    BMC pulmonary medicine, 22, 1, 449, 449, 2022年11月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Endobronchial ultrasound (EBUS)-guided transbronchial biopsy (TBB) facilitates the diagnosis of various respiratory diseases. The safety of performing EBUS-guided TBB in patients with a finding of pulmonary hypertension (PH) is controversial. Little is known about the relationship between the risk of bleeding associated with EBUS-guided TBB in the presence of PH suspected on echocardiography or chest CT. METHODS: To assess the risk of bleeding associated with EBUS-guided TBB in patients with presumed PH per echocardiography or chest CT, we retrospectively reviewed the medical records of 314 consecutive patients who underwent EBUS-guided TBB using a guide sheath (GS), as well as echocardiography and chest CT. Bleeding complication was defined as over one minute of suctioning; repeated wedging of the bronchoscope; instillation of cold saline, diluted vasoactive substances, or thrombin due to persistent bleeding. Findings of suspected PH were defined as peak tricuspid regurgitation velocity (TRV) > 2.8 m/s on echocardiography or pulmonary artery to aorta ratio (PA:A ratio) > 0.9 on chest CT. RESULTS: In total, 35 (11.1%) patients developed bleeding, and all cases were managed safely. Furthermore, 17 (5.4%) and 59 (18.8%) patients were suspected to have PH based on echocardiography and chest CT, respectively. Among the patients suspected to have PH on echocardiography, five (5/17 = 29.4%) patients developed bleeding. Among the patients suspected to have PH on chest CT, 11 (11/59 = 18.6%) patients developed bleeding. Univariate analysis revealed that long diameter (≥ 30 mm) of the lesion, lesion location (the biopsy site was inner than the segmental bronchus), bronchoscopic diagnosis of malignancy, and additional biopsy were potential predictive factors for bleeding. The finding of suspected PH on echocardiography correlated significantly with bleeding (p = 0.03). On multivariate analysis, long diameter (≥ 30 mm) of the lesion (p = .021) and findings of suspected PH on echocardiography (p = .049) were significantly associated with bleeding. CONCLUSION: All cases of bleeding in the present study were managed safely. The risk of bleeding is moderately elevated when PH is suspected by echocardiography in patients undergoing EBUS-guided TBB using a GS.
  • Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.
    Hirofumi Takahashi; Jun Sakakibara-Konishi; Megumi Furuta; Tetsuaki Shoji; Kosuke Tsuji; Daisuke Morinaga; Eiki Kikuchi; Junko Kikuchi; Takuro Noguchi; Kanako C Hatanaka; Yutaka Hatanaka; Naofumi Shinagawa; Satoshi Konno
    Cancer science, 114, 4, 1635, 1650, 2022年11月21日, [国際誌]
    英語, 研究論文(学術雑誌), Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that has shown marked antitumor activity in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, these effects are transient and most patients develop resistance. Reversible drug-tolerant persister (DTP) cells are defined as a small subpopulation of cells with markedly reduced sensitivity and non-genetic acquired resistance to EGFR-TKIs. Notch is a transmembrane receptor that plays an important role in tumorigenesis. We previously reported that there is significant crosstalk between the Notch and EGFR pathways in NSCLC. Moreover, the Notch pathway is associated with resistance to previous-generation EGFR-TKIs. However, the role of Notch in osimertinib resistance is not fully understood. In this study, we evaluated whether Notch is involved in osimertinib resistance. We show that NOTCH1 and Notch target genes are upregulated in osimertinib DTP cells, and that the addition of a γ-secretase inhibitor (GSI), a Notch inhibitor, impairs drug-tolerant persistence in vitro and in vivo. Compared with osimertinib, combined GSI and osimertinib suppress phospho-ERK partly by enhancing DUSP1 expression. Furthermore, Notch1 and HES1 were upregulated after EGFR-TKI treatment in half of human EGFR-mutated NSCLC tumor tissues. These results suggest that the combination of GSI and osimertinib may be a potential therapy for EGFR-mutated NSCLC.
  • EGFR変異陽性非小細胞肺癌におけるosimertinib耐性とNotch経路の関わり
    高橋 宏典; 榊原 純; 古田 恵; 庄司 哲明; 辻 康介; 森永 大亮; 菊地 英毅; 菊地 順子; 野口 卓郎; 畑中 佳奈子; 畑中 豊; 品川 尚文; 今野 哲
    肺癌, 62, 6, 715, 715, (NPO)日本肺癌学会, 2022年11月
    日本語
  • EBUS-GS-TBB検体の腫瘍細胞含有率に関連する臨床因子についての検討
    高島 雄太; 品川 尚文; 有里 仁希; 嘉島 相裕; 庄司 哲明; 古田 恵; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 畑中 佳奈子; 松野 吉宏; 畑中 豊; 今野 哲
    気管支学, 44, 6, 459, 459, (一社)日本呼吸器内視鏡学会, 2022年11月
    日本語
  • Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
    Yasuyuki Ikezawa; Hidenori Mizugaki; Ryo Morita; Kazunari Tateishi; Keiki Yokoo; Toshiyuki Sumi; Hajime Kikuchi; Yasuo Kitamura; Atsushi Nakamura; Maki Kobayashi; Mari Aso; Nozomu Kimura; Fumiaki Yoshiike; Megumi Furuta; Hisashi Tanaka; Motoki Sekikawa; Tsutomu Hachiya; Keiichi Nakamura; Mototsugu Shimokawa; Satoshi Oizumi
    Cancer science, 113, 6, 2109, 2117, 2022年06月, [国際誌]
    英語, 研究論文(学術雑誌), It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor proportion score ≥ 50%). We performed a retrospective, multicenter study of 300 patients with NSCLC exhibiting high PD-L1 expression who received MONO or COMB as first-line treatment between December 2018 and January 2020. We reviewed the medical records of all consecutive patients with no driver mutations, and assessed the patient characteristics, therapeutic regimens, treatment periods, and adverse events. In total, 166 (55%; median age: 74 years) and 134 (45%; median age: 68 years) patients received MONO and COMB, respectively. Patients were younger and had better performance status (0-1) in the COMB group (p < 0.01). With a median follow-up time of 10.6 (range: 0.1-20.6) months, the median progression-free survival was 7.1 months with MONO and 13.1 months with COMB. The objective response rate was 42.2% with MONO and 67.9% with COMB. With respect to treatment discontinuation, 36 out of 166 (21.7%) and 28 out of 134 (20.1%) patients discontinued MONO and COMB, respectively. In conclusion, COMB may be a promising option for first-line treatment for NSCLC with high PD-L1 expression and good performance status.
  • 肺動脈圧の上昇が疑われる症例でのEBUS-GS-TBBに伴う出血に関する検討
    高島 雄太; 品川 尚文; 山本 岳; 森永 大亮; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 中村 順一; 辻野 一三; 今野 哲
    気管支学, 43, 6, 690, 690, (一社)日本呼吸器内視鏡学会, 2021年11月
    日本語
  • 当科における悪性胸膜中皮腫に対するニボルマブ投与症例の検討
    西村 弘基; 古田 恵; 辻 康介; 葛巻 哲; 児島 裕一; 山本 岳; 伊藤 祥太郎; 國崎 守; 高島 雄太; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
    肺癌, 61, 1, 64, 64, (NPO)日本肺癌学会, 2021年02月
    日本語
  • Pregabalin Attenuates Carboplatin-Induced Akathisia-Like Neuropathy: A Novel Case Report.
    Yoshitaka Saito; Yoh Takekuma; Megumi Furuta; Mitsuru Sugawara
    Case reports in oncology, 14, 3, 1418, 1421, 2021年, [国際誌]
    英語, 研究論文(学術雑誌), Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most serious adverse effects of chemotherapy. We experienced carboplatin (CBDCA)-induced akathisia-like CIPN, which was significantly attenuated by pregabalin administration, and report its treatment. A man in his 40s was administered CBDCA + pemetrexed (PEM) as the third-line treatment for recurrent malignant pleural mesothelioma. He rarely experienced mild akathisia-like symptoms on his feet before the diagnosis. The patient claimed that he exhibited mild degradation of the symptoms in the previous cisplatin (CDDP) + PEM treatment without the need for pharmacotherapy. Symptoms notably worsened approximately 7 days after the first cycle of CBDCA + PEM and did not disappear. Furthermore, symptoms worsened during the daytime and became milder at night. Lorazepam (0.5 mg) was administered 3 times a day from day 14 but was not effective. Finally, we evaluated the symptoms to be derived from CBDCA-induced neuropathy as he experienced the same symptoms in CDDP + PEM and did not have suspicious pathology or medicines for akathisia development. We decided to administer 75 mg pregabalin twice daily, resulting in significant symptom improvement. He also complained that he felt the symptoms 10 h after the previous pregabalin dose, suggesting that pregabalin was effective, and its effect weakened or disappeared as time progressed. Akathisia-like symptoms caused by CBDCA-induced CIPN are rare, but they significantly reduce the quality of life. Pregabalin was significantly effective in this case; therefore, we suggest that a detailed symptom interview and selection of the medicine, based upon the action mechanism, are necessary.
  • 当科におけるEGFR遺伝子変異陽性非小細胞肺癌に対するデュルバルマブ使用症例の後方視的検討
    辻 康介; 水柿 秀紀; 伊藤 祥太郎; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 高島 雄太; 古田 恵; 庄司 哲明; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
    肺癌, 60, 6, 638, 638, (NPO)日本肺癌学会, 2020年10月
    日本語
  • Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
    Tetsuaki Shoji; Eiki Kikuchi; Junko Kikuchi; Yuta Takashima; Megumi Furuta; Hirofumi Takahashi; Kosuke Tsuji; Makie Maeda; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi; Satoshi Konno
    Cancer chemotherapy and pharmacology, 85, 5, 843, 853, 2020年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: We evaluated the expression of proteasome subunits to assess whether the proteasome could be a therapeutic target in cisplatin-resistant lung cancer cells. METHODS: Cisplatin-resistant (CR) variants were established from three non-small cell lung cancer (NSCLC) cell lines (A549, H1299, and H1975) and two small cell lung cancer (SCLC) cell lines (SBC3 and SBC5). The expression of proteasome subunits, the sensitivity to immunoproteasome inhibitors, and 20S proteasomal proteolytic activity were examined in the CR variants of the lung cancer cell lines. RESULTS: All five CR cell lines highly expressed one or both of the immunoproteasome subunit genes, PSMB8 and PSMB9, while no clear trend was observed in the expression of constitutive proteasome subunits. The CR cells expressed significantly higher levels of PSMB8 and PSMB9 proteins, as well. The CR variants of the H1299 and SBC3 cell lines were more sensitive to immunoproteasome inhibitors, and had significantly more proteasomal proteolytic activity than their parental counterparts. CONCLUSIONS: The immunoproteasome may be an effective therapeutic target in a subset of CR lung cancers. Proteasomal proteolytic activity may be a predictive marker for the efficacy of immunoproteasome inhibitors in cisplatin-resistant SCLC and NSCLC.
  • Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Yuta Takashima; Eiki Kikuchi; Junko Kikuchi; Motofumi Suzuki; Hajime Kikuchi; Makie Maeda; Tetsuaki Shoji; Megumi Furuta; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi; Satoshi Konno
    International journal of cancer, 146, 4, 1114, 1124, 2020年02月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Bromodomain and extraterminal domain (BET) inhibitors are broadly active against distinct types of cancer, including nonsmall cell lung cancer (NSCLC). Previous studies have addressed the effect of BET-inhibiting drugs on the expression of oncogenes such as c-Myc, but DNA damage repair pathways have also been reported to be involved in the efficacy of these drugs. AZD1775, an inhibitor of the G2-M cell cycle checkpoint kinase WEE1, induces DNA damage by promoting premature mitotic entry. Thus, we hypothesized that BET inhibition would increase AZD1775-induced cytotoxicity by impairing DNA damage repair. Here, we demonstrate that combined inhibition of BET and WEE1 synergistically suppresses NSCLC growth both in vitro and in vivo. Two BET inhibitors, JQ1 and AZD5153, increased and prolonged AZD1775-induced DNA double-strand breaks (DSBs) and concomitantly repressed genes related to nonhomologous end joining (NHEJ), including XRCC4 and SHLD1. Furthermore, pharmaceutical inhibition of BET or knockdown of the BET protein BRD4 markedly diminished NHEJ activity, and the BET-inhibitor treatment also repressed myelin transcription factor 1 (MYT1) expression and promoted mitotic entry with subsequent mitotic catastrophe when combined with WEE1 inhibition. Our findings reveal that BET proteins, predominantly BRD4, play an essential role in DSB repair through the NHEJ pathway, and further suggest that combined inhibition of BET and WEE1 could serve as a novel therapeutic strategy for NSCLC.
  • 当科におけるデュルバルマブ使用症例の後方視的検討
    辻 康介; 水柿 秀紀; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 高島 雄太; 古田 恵; 朝比奈 肇; 菊地 順子; 菊地 英毅; 榊原 純; 品川 尚文; 今野 哲
    肺癌, 59, 6, 776, 776, (NPO)日本肺癌学会, 2019年11月
    日本語
  • 当科におけるクライオバイオプシーの使用経験
    國崎 守; 品川 尚文; 辻 康介; 佐藤 理子; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 高島 雄太; 古田 恵; 庄司 哲明; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 今野 哲; 松野 吉宏
    気管支学, 41, 6, 678, 678, (NPO)日本呼吸器内視鏡学会, 2019年11月
    日本語
  • Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Megumi Furuta; Jun Sakakibara-Konishi; Hajime Kikuchi; Hiroshi Yokouchi; Hiroshi Nishihara; Hiroyuki Minemura; Masao Harada; Shigeo Yamazaki; Kenji Akie; Yuka Fujita; Kei Takamura; Tetsuya Kojima; Toshiyuki Harada; Yoshinori Minami; Naomi Watanabe; Satoshi Oizumi; Hiroyuki Suzuki; Masaharu Nishimura; Hirotoshi Dosaka-Akita; Hiroshi Isobe
    The oncologist, 24, 11, e1172-e1179, 2019年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Delta-like protein 3 (DLL3) is a Notch ligand that has an important role in the tumorigenesis of small cell lung cancer (SCLC). Recently, rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, has been developed for treating SCLC. DLL3 is a transcriptional target of the achaete-scute homolog-1 (ASCL1) transcription factor, which is involved in pulmonary neuroendocrine cell development. However, the relationship between DLL3 and/or ASCL1 expression and the clinical features of SCLC remains unknown, especially for early-stage resected SCLC. This study aimed to investigate the expression of DLL3 and ASCL1 in resected SCLC samples using immunohistochemical analysis. MATERIALS AND METHODS: We collected 95 surgically resected SCLC samples, which were formalin fixed and paraffin embedded. Immunohistochemistry staining was performed to investigate the correlation between the expression of either DLL3 or ASCL1 and clinicopathological features of study patients. RESULTS: Seventy-seven (83%) of 93 immunohistochemically evaluable samples were positive for DLL3 (expression in ≥1% of tumor cells), and DLL3-high expression (≥75%) was observed in 44 samples (47%). Sixty-one (64%) of 95 samples were positive for ASCL1 (expression in ≥5% of tumor cells). A positive correlation was observed between DLL3 and ASCL1 expression. DLL3 and ASCL1 expression were not associated with survival in SCLC patients. DLL3 was more prevalent in patients with advanced clinical disease. CONCLUSION: DLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 may be targets for the treatment of SCLC. IMPLICATIONS FOR PRACTICE: This article examines the relationship between delta-like protein 3 (DLL3) and achaete-scute homolog-1 (ASCL1) protein expression with the clinical features of 95 surgically resected small cell lung cancer (SCLC). DLL3 is attracting attention because rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, was developed recently. DLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 may be targets for the treatment of early-stage SCLC, including with Rova-T.
  • DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Megumi Furuta; Hajime Kikuchi; Tetsuaki Shoji; Yuta Takashima; Eiki Kikuchi; Junko Kikuchi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Jun Sakakibara-Konishi
    Cancer science, 110, 5, 1599, 1608, 2019年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Delta-like protein 3 (DLL3) is a ligand of Notch signaling, which mediates cell-fate decisions and is tumor-suppressive or oncogenic depending on the cellular context. Previous studies show that DLL3 is highly expressed in small cell lung cancer (SCLC) but not in normal lung tissue, suggesting that DLL3 might be associated with neuroendocrine tumorigenesis. However, its role in SCLC remains unclear. To investigate the role of DLL3 in tumorigenesis in SCLC, we performed loss-of-function and gain-of-function assays using SCLC cell lines. In vitro analysis of cell migration and invasion by transwell assay showed that DLL3 knockdown reduced migration and invasion of SCLC cells, whereas DLL3 overexpression increased these activities. In addition, DLL3 positively regulated SNAI1 expression and knockdown of SNAI1 attenuated the migration and invasion ability of SCLC cells. Moreover, upregulated DLL3 expression induced subcutaneous tumor growth in mouse models. These results indicate that DLL3 promoted tumor growth, migration and invasion in an SCLC model by modulating SNAI1/Snail.
  • 当院におけるFFPE検体、細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
    北井 秀典; 榊原 純; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 品川 尚文; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 大井 優子
    肺癌, 59, 1, 112, 112, (NPO)日本肺癌学会, 2019年02月, [査読有り]
    日本語
  • Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma.
    Hajime Kikuchi; Jun Sakakibara-Konishi; Megumi Furuta; Eiki Kikuchi; Junko Kikuchi; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
    Oncotarget, 9, 50, 29379, 29391, 2018年06月29日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Some reports suggest that Numb is a potential tumor suppressor. However, its role in non-small cell lung cancer remains unclear. Non-small cell lung cancer comprises two major histological subtypes, adenocarcinoma and squamous cell carcinoma. To investigate the role of Numb in tumorigenesis of lung adenocarcinoma and squamous cell carcinoma, we firstly performed loss-of-function and gain-of-function assays. Moreover, Numb expression was investigated in surgically resected lung adenocarcinoma and squamous cell carcinoma tissues by immunohistochemistry and correlations with prognosis were analyzed. Numb suppressed the proliferation, migration, and invasion of adenocarcinoma cells and inhibited Notch signaling and epithelial-mesenchymal transition in vitro. Numb overexpression also inhibited subcutaneous adenocarcinoma tumor growth. In contrast, Numb promoted the proliferation, migration, and invasion of squamous cell carcinoma cells, but did not induce any consistent changes in Notch signaling. High Numb expression was associated with favorable prognosis in patients with lung adenocarcinoma, but not in those with squamous cell carcinoma. Collectively, our data demonstrate that Numb plays distinct roles in lung adenocarcinoma and squamous cell carcinoma. In lung adenocarcinoma, Numb impairs tumor growth and inhibits the Notch pathway and epithelial-mesenchymal transition, whereas in lung squamous cell carcinoma it may promote proliferation.
  • Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
    Tetsuaki Shoji; Hidenori Mizugaki; Yasuyuki Ikezawa; Megumi Furuta; Yuta Takashima; Hajime Kikuchi; Houman Goudarzi; Hajime Asahina; Junko Kikuchi; Eiki Kikuchi; Jun Sakakibara-Konishi; Naofumi Shinagawa; Ichizo Tsujino; Masaharu Nishimura
    Internal medicine (Tokyo, Japan), 57, 12, 1769, 1772, 2018年06月15日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.
  • A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
    Yasuyuki Ikezawa; Hajime Asahina; Satoshi Oizumi; Masahiro Watanabe; Kei Takamura; Yasutaka Kawai; Noriyuki Yamada; Toshiyuki Harada; Ichiro Kinoshita; Yuka Fujita; Eisaku Miyauchi; Takahiro Ogi; Toraji Amano; Megumi Furuta; Jun Sakakibara-Konishi; Hiroshi Nishihara; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
    Cancer chemotherapy and pharmacology, 80, 5, 955, 963, 2017年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Expression of Notch1 and Numb in small cell lung cancer.
    Hajime Kikuchi; Jun Sakakibara-Konishi; Megumi Furuta; Hiroshi Yokouchi; Hiroshi Nishihara; Shigeo Yamazaki; Hidetaka Uramoto; Fumihiro Tanaka; Masao Harada; Kenji Akie; Fumiko Sugaya; Yuka Fujita; Kei Takamura; Tetsuya Kojima; Toshiyuki Harada; Mitsunori Higuchi; Osamu Honjo; Yoshinori Minami; Naomi Watanabe; Satoshi Oizumi; Hiroyuki Suzuki; Takashi Ishida; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Mitsuru Munakata; Masaharu Nishimura
    Oncotarget, 8, 6, 10348, 10358, 2017年02月07日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Usefulness of Endobronchial Ultrasonography With a Guide Sheath and Virtual Bronchoscopic Navigation for Ground-Glass Opacity Lesions
    Yasuyuki Ikezawa; Naofumi Shinagawa; Noriaki Sukoh; Megumi Morimoto; Hajime Kikuchi; Masahiro Watanabe; Kosuke Nakano; Satoshi Oizumi; Masaharu Nishimura
    ANNALS OF THORACIC SURGERY, 103, 2, 470, 475, 2017年02月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
■ 主な担当授業
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ 共同研究・競争的資金等の研究課題
  • 小細胞肺癌におけるDLL3の機能及び遺伝子異常の検討
    科学研究費助成事業
    2020年04月01日 - 2022年03月31日
    古田 恵
    SCLC細胞株でDLL3をknockdownすると遊走能・浸潤能が低下し、Snailの発現は減弱した。逆にDLL3をoverexpressionすると増殖能・遊走能は亢進し、Snailの発現は増加し、DLL3はEMTを調節する転写因子であるSnailを介して遊走能・浸潤能亢進に関与している可能性が考えられた。ゼノグラフトマウスモデルを用いて評価した腫瘍増殖はDLL3をoverexpressionさせたSBC-5でコントロールと比較して亢進しており、摘出腫瘍のSnail 発現はコントロール群腫瘍と比べ発現が増加しており、in vitroと同様の結果であった。
    日本学術振興会, 若手研究, 北海道大学, 20K16349
  • 小細胞肺癌におけるDLL3の機能及び遺伝子異常の検討
    科学研究費助成事業
    2019年08月30日 - 2021年03月31日
    古田 恵
    SCLC細胞株でDLL3をknockdownすると遊走能・浸潤能が低下し、Snailの発現は減弱した。逆にDLL3をoverexpressionすると増殖能・遊走能は亢進し、Snailの発現は増加し、DLL3はEMTを調節する転写因子であるSnailを介して遊走能・浸潤能亢進に関与している可能性が考えられた。ゼノグラフトマウスモデルを用いて評価した腫瘍増殖はDLL3をoverexpressionさせたSBC-5でコントロールと比較して亢進しており、摘出腫瘍のSnail 発現はコントロール群腫瘍と比べ発現が増加しており、in vitroと同様の結果であった。
    日本学術振興会, 研究活動スタート支援, 北海道大学, 19K23903